The modality is outside your comfort zone
Your partners can follow the deck. They cannot quickly stress-test what must be true across biology, manufacturing, and the path to clinic—or spot where prior packages in the class failed.
BioticaBio
Independent science diligence · seed & Series A
Know what has to be true—before you write the check.
You are about to put $1–10M into a complex biotech or medtech package. BioticaBio turns the pitch into the claims that must hold for the deal to work, checks each one against published science and known failures, and returns a source-linked memo your partners can inspect: what holds, what conflicts, and what is still unknown.
Tempus is a major precision-medicine company that uses biomedical data and knowledge graphs to pressure-test drug-development hypotheses for industry. BioticaBio does the parallel job for investors: pressure-test the investment thesis against the published evidence graph, then write the implications for your partners.
Decision Sprint · fixed scope · NDA before data room · timed to your deal deadline
- Lean seed & Series A teams
- $1–10M biotech / medtech checks
- Live deal under a deadline
- Claims checked against published science
- Source-linked partner memo
- NDA before the data room
When buyers call us
You are not looking for more slides. You are looking for a defensible call.
A clean mechanism still dies on translation, CMC, differentiation, or financing. We make those dependencies explicit—so you walk into the partner meeting knowing where the thesis is strong, contested, or empty.
The evidence cuts both ways
There is real support and real contradiction. You need a written map: which claims hold against the literature and trials, which rest on inference, and what to ask management before you commit.
The clock is real and the bench is thin
You have a partner meeting or term-sheet deadline and no full cross-functional diligence team. You need outside science scrutiny sized to that decision—not a multi-month consulting engagement.
What you buy
One Decision Sprint on the live deal. A short triage if you are not ready to go deep.
Independent scientific diligence for lean seed and Series A teams: take one opportunity, pressure-test the science case, and deliver a memo your partners use in the decision meeting.
Primary · Decision Sprint
Science diligence on one live opportunity—claims checked against published evidence, written for the investment decision.
- Pricing
- On inquiry
- Timing
- Your deal clock
- You walk away with
- Partner-ready memo
- Two-page decision brief + claim-by-claim evidence map with sources
- Risk register, prior-failure context, and questions for management
- ~20–30 page memo and a 60-minute partner briefing
Optional · Signal Screen
Five-claim triage before you open the full sprint
Deck plus public sources only. Pricing on inquiry—credited toward a Decision Sprint started within 30 days when scoped after the screen. Use it when you need a fast dig-deeper / pass signal before locking full scope.
Not the lead offer. Ask for it after fit discussion.
Mention Signal Screen in your fit request →Prior modality work
The classes investors ask us to cut before they commit.
Anonymized accounts of live-deal pressure—claims tested, triggers surfaced, sprint boundaries—without client names or outcomes.
Non-specific work account
Cell therapy
Early investment and partnership reviews of autologous and allogeneic cell programs, including platform-plus-pipeline structures where the thesis mixed product claims with manufacturing and control-strategy readiness.
Decision pressure
Term-sheet timing forced a sharp cut between what was demonstrated in limited clinical/process packages versus what still depended on unproven scale, release, or comparability assumptions.
Boundary
Did not substitute for formal CMC, regulatory, or clinical-statistical opinions; flagged when those were required.
Claims typically pressure-tested
- Whether potency and product identity claims were decision-grade for the proposed next study
- Whether CMC / process control risk would consume the raise before a claim-resolving readout
- Whether comparator and failed-analogue programs actually supported the differentiation story
Example decision triggers surfaced
- Potency assay or release strategy not yet tied to the clinical claim
- Comparability after process change left as narrative rather than a plan
- Use of proceeds not mapped to the must-be-true manufacturing gates
Related decision notes
Accounts are intentionally non-specific. Client identities, confidential findings, and investment outcomes are omitted. These describe types of diligence pressure-tests performed — not case studies with results.
Who this is for
Fit and not fit—stated plainly.
Pricing is set from the inquiry: modality complexity, evidence access, deadline, and scope. Optional Signal Screen is available after fit discussion—not as the homepage lead.
Fit
- U.S. seed / Series A investor writing $1–10M biotech or medtech checks
- Technically complex package—advanced therapeutics, diagnostics, or regulated devices
- A live decision with a real clock (partner meeting, term sheet, syndication, follow-on)
- Thin or incomplete internal science / CMC / regulatory bench for this modality
- Willingness to put the thesis under adversarial pressure—not looking for cheerleading
Not fit
- Mega-funds that already staff complete specialist diligence benches
- Buyers who need legal FTO, regulatory sign-off, audit, or clinical-statistical reanalysis
- Founders seeking promotional validation of a pitch
- Zero-budget angels or general market-education projects
- Deals where source access makes the stated deadline fake
Questions investors ask first
Straight answers.
We are a lean team without a full biotech diligence bench. Is this for us?
Yes—when you have a live $1–10M decision on a technically complex opportunity. BioticaBio is built for lean seed and Series A teams that need an independent, inspectable science view before they commit—not a permanent outsourced specialist shop.
How is pricing set?
On inquiry. Quote follows fit discussion and depends on modality complexity, evidence access, deadline, and scope. There is no public rate card on this site.
How is this different from a large life-science diligence firm?
Large firms staff matched specialists across clinical, CMC, regulatory, IP, and commercial for full transactions. We do something narrower and more decision-shaped: pull the claims that must be true for your deal, check them against published literature, trials, targets, and known failures, and write what that means for the investment call. Domains outside scope stay listed as unreviewed.
What does the knowledge graph do?
It links biomedical evidence—papers, trials, targets, labels, patents, failure modes—so each material claim is checked for support and contradiction, not retold from the deck. A human owns the investment synthesis. You get sources attached. You do not get a black-box score.
Go deeper
Method, prior work, and operating detail live on their own pages.
Have a live deal on the calendar?
Tell us stage, modality, deadline, and the claims creating the most uncertainty. We reply on fit within one business day—before any confidential materials change hands.
Scope a live deal
For $1–10M biotech and medtech checks. No file uploads on this form.